Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready • 4 patents granted in the last 365 days
National Institute Of Biological Sciences Beijing has 1 pending office action in Biotechnology & Pharmaceuticals. Its record includes 1 distinct examiner and 1 distinct art unit, indicating one examination path for the current matter.
VIJAYARAGHAVAN, JAGAMYA NMN is the busiest examiner and handles the pending action. Practitioners can focus the response on the examiner’s analysis of the biotechnology disclosure and claim scope.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| VIJAYARAGHAVAN, JAGAMYA NMN | 1 | 61.0% | +51.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | VIJAYARAGHAVAN, JAGAMYA NMN | 25d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | VIJAYARAGHAVAN, JAGAMYA NMN | 25d overdue |
| Art Unit | Apps |
|---|---|
| 1633 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17614673 | DRUG TARGET OF IDIOPATHIC PULMONARY FIBROSIS | VIJAYARAGHAVAN, JAGAMYA NMN | 1633 | §102§112Other | Non-Final OA | 25d overdue | Pending | Nov 29, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialNational Institute Of Biological Sciences Beijing has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jagamya Nmn Vijayaraghavan has the most, with 1 of National Institute Of Biological Sciences Beijing's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
